COMMUNIQUÉS West-GlobeNewswire

Advanced Accelerator Applications Announces Commencement of Novartis Tender Offer
07/12/2017
SAINT-GENIS-POUILLY, France, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ: AAAP ) (AAA or the Company), a leader in nuclear medicine theragnostics, today announced that a direct and [...]
Akcea to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
07/12/2017
CAMBRIDGE, Mass., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA ), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious [...]
CRISPR Therapeutics Submits First Clinical Trial Application for a CRISPR Gene-Edited Therapy, CTX001 in β-thalassemia
07/12/2017
ZUG, Switzerland and CAMBRIDGE, Mass., Dec. 07, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP ) today announced the submission of a Clinical Trial Application (CTA) for CTX001 in β-thalassemia. CTX001 is an [...]
Nightstar Therapeutics to Participate in BMO Prescriptions for Success Healthcare Conference
07/12/2017
LEXINGTON, Mass. and LONDON, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ: NITE ), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced [...]
Pluristem to Present Data on PLX-R18 in Treatment of Acute Radiation Syndrome at American Society of Hematology’s Annual Meeting
07/12/2017
Data from Phase II-equivalent study demonstrated improved survival and hematological recovery of non-human primates (NHP) exposed to high levels of radiation PLX-R18 cells are in late-stage development as a treatment [...]
SuperSonic Imagine Installs Six Aixplorer® Ultimate Ultrasound Systems at 'Occitanie-Garonne' Medical Imaging Group
07/12/2017
AIX-EN-PROVENCE, France, Dec. 07, 2017 (GLOBE NEWSWIRE) -- SuperSonic Imagine (Euronext:SSI FR0010526814), a company specialising in medical imaging using ultrasound, announced today that it installed six Aixplorer [...]
Tresiba® reduces hypoglycaemia regardless of blood sugar level
07/12/2017
Abu Dhabi, UAE, 7 December 2017 - People with either type 1 or type 2 diabetes treated with Tresiba ® had fewer episodes of low blood sugar (hypoglycaemia) compared with people on insulin glargine U100 regardless of [...]
Ryzodeg® significantly reduces the risk of low blood sugar in people with type 2 diabetes who fast during Ramadan
07/12/2017
Abu Dhabi, UAE, 7 December 2017 - In people with type 2 diabetes who fast during Ramadan, Ryzodeg ® (insulin degludec/insulin aspart) reduced the overall rate of low blood sugar (hypoglycaemia) including severe [...]
PRICING AND FURTHER DETAILS ON THE OFFERING OF NEW SHARES IN ALK-ABELLÓ A/S
07/12/2017
Copenhagen, 2017-12-07 08:01 CET (GLOBE NEWSWIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, [...]
OSE Immunotherapeutics to Resume Accrual in Phase 3 Clinical Trial of Tedopi® in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment
07/12/2017
Independent Data Monitoring Committee recommends future recruitment focused on patients who have previously failed immune checkpoint inhibitor treatment New strategy adjusts for rapidly-evolving clinical practice with [...]
ABLYNX WILL HOST A WEBCAST TO DISCUSS ADDITIONAL DATA FROM ITS PHASE III HERCULES STUDY OF CAPLACIZUMAB IN ACQUIRED TTP FOLLOWING ASH LATE-BREAKING DATA PRESENTATION
07/12/2017
GHENT, Belgium, 7 December 2017 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX] announced today that the Ablynx management team will host a conference call and webcast to present additional data from the Phase III [...]
Novartis tender offer for Advanced Accelerator Applications commences
07/12/2017
Basel, December 7, 2017 - Novartis AG (NYSE: NVS) ("Novartis") today announced that its direct and indirect subsidiary, Novartis Groupe France S.A., a société anonyme organized under the laws of France ("Purchaser"), [...]
INNATE PHARMA ANNOUNCES ITS FINANCIAL CALENDAR FOR 2018
07/12/2017
Innate Pharma announceS ITS FINANCIAL CALENDAR FOR 2018 Marseille, France, December 7, 2017, 7:00 AM CET Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announces its financial calendar for [...]
INNATE PHARMA ANNONCE SON CALENDRIER FINANCIER POUR 2018
07/12/2017
INNATE PHARMA ANNONCE SON CALENDRIER FINANCIER POUR 2018 Marseille, le 7 décembre 2017, 7h00 CET Innate Pharma SA (Euronext Paris : FR0010331421 - IPH) annonce aujourd'hui son calendrier financier pour l'année 2018 : 8 [...]
INNATE PHARMA : NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS AT DECEMBER 4, 2017
07/12/2017
NUMBER OF SHARES AND VOTING RIGHTS OF Innate Pharma AS AT December 4, 2017 Marseille, France, December 7, 2017, 7:00 AM CET Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 [...]
INNATE PHARMA : NOUVEAU NOMBRE D'ACTIONS ET DE DROITS DE VOTE D'INNATE PHARMA AU 4 DECEMBRE 2017
07/12/2017
nouveau NOMBRE D'ACTIONS ET DE DROITS DE VOTE d'InnatE Pharma AU 4 décembre 2017 Marseille, le 7 décembre 2017, 7h00 CET Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l' [...]
GW Pharmaceuticals plc Announces Pricing of Public Offering of ADSs Raising Gross Proceeds of $276 Million
07/12/2017
LONDON, Dec. 06, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH ) ("GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its [...]
Resverlogix Repays $68.8 Million Loan
07/12/2017
CALGARY, Alberta, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX ) announced today that it has repaid, in full, its CAD$68.8 million Loan (the “Loan”). Upon repayment of [...]
Myriad Genetics Presents Pivotal Validation Study for New riskScore™ Test at the 2017 San Antonio Breast Cancer Symposium
07/12/2017
SALT LAKE CITY, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN ), a leader in molecular diagnostics and personalized medicine, today announced results from a ground-breaking validation study to [...]

Pages